No Data
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results From Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
Express News | Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results From Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at Acaai 2024
Celldex Therapeutics, Inc. (CLDX): Hedge Funds' Hidden Gem in Small-Cap Stocks
Goldman Sachs Maintains Celldex Therapeutics(CLDX.US) With Hold Rating, Maintains Target Price $45
Jasper Gains 11% on Data for Briquilimab in Urticaria
Citi Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $70